April 2018 – Straight to the Heart

Certain cancers and their treatments can lead to heart problems. Generally this occurs in three ways: 1) cancer can metastasize to the heart or its lining 2) certain rare tumors can release chemicals into the bloodstream that damage the heart’s valves and muscles 3) certain white blood cell tumors secrete proteins that become sticky deposits…

Read More

Janurary 19, 2018 – Single Blood Test Screens for Eight Cancer Types

John Hopkins Kimmel Cancer Center researchers developed a single blood test that can detect for eight common cancer types through assessment of the circulating proteins and mutations in cell-free DNA. The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer proteins and the presence of cancer gene mutations from…

Read More

September 22, 2017 – FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1

Today, Merck announced that the FDA has approved the anti-PD-1 therapy, Keytruda (pembrolizumab) for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1. This makes Keytruda the first PD-1 checkpoint inhibitor approved in the United States for previously treated gastric or GEJ cancer. Treatment Options…

Read More

August 04, 2017- Reconstruction Method in Gastric CA Surgery Affects Bone Density

The standard reconstruction method may affect postoperative bone mineral density (BMD) loss in gastric cancer according to a study published in the Journal of Gastroenterology and Hepatology. In multivariate analysis, researchers found that R-Y reconstruction was an independent risk factor for BMD loss after distal gastrectomy. B-I reconstruction was found to have superiority over R-Y…

Read More

June 21, 2017- Docetaxel-Based Triplet New Standard in Gastric Cancer

A new standard of treatment of care for resectable gastric or gastroesophageal (GEJ) adenocarcinoma is perioperative chemotherapy with docetaxel-based triplet. The MAGIC trial established perioperative epirubicin, cisplatin, and fluorouracil (ECF) as a standard of treatment for patients with operable esophagogastric cancer, but outcomes remain unsatisfactory. With the new method of treatment, docetaxel-based triplet FLOT, the…

Read More

June 20, 2017- Work Related Stress and Cancer: Recent Study Examines the Connection

Researchers from the University of Quebec and University of Montreal conducted a study on how prolonged exposure to work-related stress can greatly impact an individual’s health and may increase their risks of developing certain kinds of cancers. The results showed that employment in at least one stressful job increase the odds of various cancers, including…

Read More

June 13, 2017 – Dr. Fuchs Discusses Immunotherapy in Gastric Cancer

Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smillow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, and a member of the Debbie’s Dream Foundation Medical Advisory Board discusses new strides in immunotherapy for treating gastric cancer. While therapies are common in the treatment of various cancers, Dr. Fuchs emphasizes the…

Read More